Progress of Infection and Replication Systems of Hepatitis B Virus

• Published in: ACS pharmacology & translational science 2024-06, Vol.7 (6), p.1711-1721
• Main Authors: Zhang, Tiantian, Yang, Juan, Gao, He, Wu, Yuwei, Zhao, Xinyu, Zhao, Hui, Xie, Xinqiang, Yang, Lingshuang, Li, Ying, Wu, Qingping
• Format: Article
• Language: English
• ISSN: 2575-9108; 2575-9108
• DOI: 10.1021/acsptsci.4c00147

Despite the long-standing availability of effective prophylaxis, chronic hepatitis B virus (HBV) infection remains a formidable public health threat. Antiviral treatments can limit viral propagation, but prolonged therapy is necessary to control HBV replication. Robust in vitro models of HBV infection are indispensable prerequisites for elucidating viral pathogenesis, delineating virus-host interplay and developing novel therapeutic, preventative countermeasures. Buoyed by advances in molecular techniques and tissue culture systems, investigators have engineered numerous in vitro models of the HBV life cycle. However, all current platforms harbor limitations in the recapitulation of natural infection. In this article, we comprehensively review the HBV life cycle, provide an overview of existing in vitro HBV infection and replication systems, and succinctly present the benefits and caveats in each model with the primary objective of constructing refined experimental models that closely mimic native viral infection and offering robust support for the ambitious “elimination of hepatitis by 2030” initiative.